Two Yardsticks Published in Annals of Allergy, Asthma and Immunology – Third on the Way

ARLINGTON HEIGHTS, Ill. (December 20, 2022)– Beginning in 2016, American College of Allergy,Asthma is a chronic, inflammatory lung disease characterized by recurrent breathing problems. People with asthma have acute episodes where the air passages in their lungs get narrower, and breathing becomes more difficult. Sometimes episodes of asthma are triggered by allergens, although infection, exercise, cold air and other factors are also important triggers." rel="tooltip">Asthmaand Immunology (ACAAI) began developing a series of yardsticks to help practitioners better understand the range of treatments available for allergic conditions.

Two new yardsticks,Clinical Guidance for the Use of Dupilumab in Eosinophilic Esophagitis: A YardstickandYardstick for Managing Cough. Part 1: in Adults and Adolescent Patients >14 years of agehave been published inAnnals of Allergy, Asthma and Immunology, ACAAI’s scientific journal. Part 2 of the Managing Cough yardstick will be published in the coming months. ACAAI Yardsticks differ from Practice Parameters in several ways:

Yardsticks:

• Are chosen by the College’s Yardstick Task Force and ratified by the Board of Regents. Usually, two yardsticks are published each year. No pharmaceutical support is accepted for yardsticks.
• Are developed by College experts and others.
• Provide practical, concise, evidence-based recommendations to assist with everyday clinical decision-making.
• Address important areas that are not included in other guidelines.
• Can reflect standards of care that do not meet “GRADE” criteria yet are based on evidence and best practice consensus.
• Can be rapidly updated to reflect new treatment options and reflect best practices that don’t meet strict practice parameter criteria.

The eosinophilic esophagitis (EoE) yardstick provides interval guidance for the use of dupilumab for EoE based on expert opinion. The yardstick expands on the existing Joint Task Force-AGA guidelines published in 2020 providing specific clinical scenarios in which dupilumab, the first and only FDA-approved EoE treatment, may prove useful. It also summarizes a framework for shared decision making as the certainty of evidence for most recommendations for EoE treatments is low.

Standard, evidence-based approaches to diagnosing and managing acute, subacute and chronic cough in adults and adolescents older than 14 years of age are covered in part 1 of the cough yardstick. The diagnosis and management of cough in children is discussed in part 2. Coughs of undifferentiated duration are the single most common complaint for which patients of all ages seek medical care from primary care physicians in the ambulatory care setting in the United States. In the United States alone, it is estimated that consumers spend $6.8 billion annually for over-the-counter cough and cold remedies, many of which aren’t effective, and can be harmful to young children.

About ACAAI
ACAAI是密苏里州的专业医疗机构re than 6,000 allergists-immunologists and allied health professionals, headquartered in Arlington Heights, Ill. The College fosters a culture of collaboration and congeniality in which its members work together and with others toward the common goals of patient care, education, advocacy, and research. ACAAI allergists are board-certified physicians trained to diagnose allergies and asthma, administerImmunotherapy is a form of preventive and anti-inflammatory treatment of allergy to substances such as pollens, house dust mites, fungi, and stinging insect venom. Immunotherapy involves giving gradually increasing doses of the substance, or allergen, to which the person is allergic. The incremental increases of the allergen cause the immune system to become less sensitive to the substance, perhaps by causing production of a particular "blocking" antibody, which reduces the symptoms of allergy when the substance is encountered in the future." rel="tooltip">immunotherapy, and provide patients with the best treatment outcomes. For more information and to find relief, visitAllergyandAsthmaRelief.org. Join us onFacebook,PinterestandTwitter.